Shares of Moderna have moved -1.2% today, and are now trading at a price of $24.16. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 5,983,800 compared to the stock's average volume of 9,627,831.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. Based in Cambridge, United States the company has 5,800 full time employees and a market cap of $9,402,118,144.
The company is now trading -46.83% away from its average analyst target price of $45.45 per share. The 20 analysts following the stock have set target prices ranging from $15.0 to $198.0, and on average give Moderna a rating of hold.
Over the last 12 months MRNA shares have declined by -68.4%, which represents a difference of -83.5% when compared to the S&P 500. The stock's 52 week high is $79.96 per share and its 52 week low is $23.15. Based on Moderna's average net margin growth of 29.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 3,236,000 | -3,561,000 | -110 | -59.42 |
| 2023 | 6,848,000 | -4,714,000 | -69 | -260.47 |
| 2022 | 19,263,000 | 8,362,000 | 43 | -34.85 |
| 2021 | 18,471,000 | 12,202,000 | 66 | 170.97 |
| 2020 | 803,000 | -747,000 | -93 | 89.15 |
| 2019 | 60,000 | -514,000 | -857 |
